Internal Reference Number: FOI_7926
Date Request Received: 09/05/2024 00:00:00
Date Request Replied To: 29/05/2024 00:00:00
This response was sent via: By Email
Request Summary: Intra-vitreal injections or implants
Request Category: Companies
| Question Number 1: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2024: • Aflibercept • Bevacizumab - Avastin • Bevacizumab - Biosimilar • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis (pre-filled syringes) • Ranibizumab - Lucentis (vials) • Ranibizumab – Ongavia | |
| Answer To Question 1: • Aflibercept 1043 • Bevacizumab – Avastin <5 • Bevacizumab – Biosimilar 0 • Brolucizumab 0 • Dexamethasone 14 • Faricimab 736 • Fluocinolone acetonide 0 • Ranibizumab - Lucentis (pre-filled syringes) 5 • Ranibizumab - Lucentis (vials) 0 • Ranibizumab – Ongavia 0 | |
| Question Number 2: Please see attached questions | |
| Answer To Question 2: See attached table. To accompany this answer to question 2 please also see the documents listed below:  7926 - Q2 - intra-vitreal injections or implants.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
